Plasma homocysteine and immune activation in patients with malignant melanoma undergoing treatment with IFN-α

Journal of Interferon and Cytokine Research

Volumn 24, Issue 5, 2004, Pages 311-317

  Frick, Barbara ^a   Capuron, Lucile ^b   Schröcksnadel, Katharina ^a   Musselman, Dominique L ^b   Lawson, David H ^b   Nemeroff, Charles B ^b   Miller, Andrew H ^b   Fuchs, Dietmar ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYANOCOBALAMIN; CYSTEINE; HOMOCYSTEINE; KYNURENINE; NEOPTERIN; TRYPTOPHAN;

ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HEMOCONCENTRATION; HUMAN; IMMUNE RESPONSE; MACROPHAGE; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; INTERFERON ALFA-2B; KYNURENINE; MACROPHAGE ACTIVATION; MALE; MELANOMA; MIDDLE AGED; NEOPTERIN; PREDICTIVE VALUE OF TESTS; TRYPTOPHAN; VITAMIN B 12;

EID: 2442507571     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999004323065101     Document Type: Article

References (31)

1. UELAND, P.M., and REFSUM, H. (1989). Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J. Lab. Clin. Med. 114, 473-501.
2. EIKELBOOM, J.W., LONN, E., GENEST, J., HANKEY, G., and YUSUF, S. (1999). Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann. Intern. Med. 131, 363-375.
3. BELL, I.R., EDMAN, J.S., SELHUB, J., MORROW, F.D., MARBY, D.W., KAYNE, H.L., and COLE, J.O. (1992). Plasma homocysteine in vascular disease and in nonvascular dementia of depressed elderly people. Acta Psychiatr. Scand. 86, 386-390.
4. SCHROECKSNADEL, K., FRICK, B., WIRLEITNER, B., SCHENNACH, H., and FUCHS, D. (2003). Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin. Exp. Immunol. 134, 53-56.
5. FUCHS, D., JAEGER, M., WIDNER, B., WIRLEITNER, B., ARTNER-DWORZAK, A., and LEBLHUBER, F. (2001). Is hyperhomocysteinemia due to oxidative depletion of folate rather than insufficient dietary intake? Clin. Chem. Lab. Med. 39, 691-694.
6. WIDNER, B., LEBLHUBER, F., FRICK, B., LAICH, A., ARTNER-DWORZAK, E., and FUCHS, D. (2002). Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease. J. Neural Transm. 109, 1445-1452.
7. WU, L.L., and WU, J.T. (2002). Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin. Chim. Acta 322, 21-28.
8. HOFFMAN, R.M. (1985). Altered methionine metabolism and transmethylation in cancer. Anticancer Res. 5, 1-30.
9. SUN, C.F., HAVEN, T.R., WU, T.L., TSAO, K.C., and WU, J.T. (2002). Serum total homocysteine increases with the rapid proliferation rate of tumor cells and declines upon cell death: a potential new tumor marker. Clin. Chim. Acta 321, 55-62.
10. GASTL, G., AULITZKY, W., TILG, H., NACHBAUR, K., TROPPMAIR, J., FLENER, R., and HUBER, C. (1986). A biological approach to optimize interferon treatment in hairy cell leukemia. Immunobiology 172, 262-268.
11. SCHILLER, J.H., HANK, J., STORER, B., BORCHERT, A.A., MOORE, K.H., ALBERTINI, M., BECHHOFER, R., WESLEY, O., BROWN, R.R., and BASTIN, A.M. (1993). A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans. Cancer Res. 53, 1286-1292.
12. 2-microglobulin and interferon-γ in patients with chronic hepatitis C treated with interferon-α2b. Eur. J. Med. 1, 196-200.
13. HUBER, C., BATCHELOR, J.R., FUCHS, D., HAUSEN, A., LANG, A., NIEDERWIESER, D., REIBNEGGER, G., SWETLY, P., TROPPMAIR, J., and WACHTER, H. (1984). Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J. Exp. Med. 160, 310-316.
14. WIRLEITNER, B., REIDER, D., EBNER, S., BÖCK, G., WIDNER, B., JAEGER, M., SCHENNACH, H., ROMANI, N., and FUCHS, D. (2002). Monocyte-derived dendritic cells release neopterin. J. Leukocyte Biol. 72, 1148-1153.
15. BYRNE, G.I., LEHMANN, L.K., KIRSCHBAUM, J.G., BORDEN, E.C., LEE, C.M., and BROWN, R.R. (1986). Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity. J. Interferon Res. 6, 389-396.
16. FUCHS, D., MÖLLER, A.A., REIBNEGGER, G., STÖCKLE, E., WERNER, E.R., and WACHTER, H. (1990). Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J. Acquir. Immune Defic. Syndr. 3, 873-876.
17. WIDNER, B., WERNER, E.R., SCHENNACH, H., WACHTER, H., and FUCHS, D. (1997). Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin. Chem. 43, 2424-2426.
18. FRICK, B., SCHRÖCKSNADEL, K., NEURAUTER, G., WIRLEITNER, B., ARTNER-DWORZAK, E., and FUCHS, D. (2003). Rapid measurement of total plasma homocysteine by HPLC. Clin. Chim. Acta 331, 19-23.
19. FRICK, B., RUDZITE, V., SCHRÖCKSNADEL, K., KALNINS, U., ERGLIS, A., TRUSINSKIS, K., and FUCHS, D. (2003). Homocysteine, B vitamins and immune activation in coronary heart disease. Pteridines 13, 82-87.
20. 6 and one carbon metabolism. J. Nutr. Health Aging 6, 39-42.
21. GRÜNGREIFF, K., REINHOLD, D., and ANSORGE, S. (1999). Serum concentrations of sIL-2R, IL-6, TGF-β1, neopterin and zinc in chronic hepatitis C patients treated with interferon-alpha. Cytokine 11, 1076-1080.
22. CASTELLO, G., COMELLA, P., MANZO, T., NAPOLITANO, M., PARZIALE, A.P., GALATI, M.G., DAPONTE, A., CASARETTI, R., CELENTANO, E., and COMELL, A.G. (1993). Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma. Melanoma Res. 3, 43-49.
23. REFSUM, H., WESENBERG, F., and UELAND, P.M. (1991). Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res. 51, 828-835.
24. NATHAN, C.F., MURRAY, H.W., WIEBE, M.E., and RUBIN, B.Y. (1983). Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 158, 670-689.
25. LAICH, A., LEBLHUBER, F., WIDNER, B., FRICK, B., JELLINGER, K., and FUCHS, D. (2002). Moderate hyperhomocy-steinemia in patients with Huntington's disease. Pteridines 13, 121-125.
26. GOTTSATER, A., ANWAAR, I., ERIKSSON, K.P., MATTIASSON, I., and LINDGARDE, F. (2000). Homocysteine is related to neopterin and endothelin-1 in plasma of subjects with disturbed glucose metabolism and reference subjects. Angiology 51, 489-497.
27. TURGAN, N., HABIF, S., PARILDAR, Z., OZMEN, D., MUTAF, I., ERDENER, D., and BAYINDIR, O. (2001). Association between homocysteine and neopterin in healthy subjects measured by a simple HPLC-fluorometric method. Clin. Biochem. 34, 271-275.
28. LU, G., SHIMIZU, I., CUI, X., ITONAGA, M., TAMAKI, K., FUKUNO, H., INOUE, H., HONDA, H., and ITO, S. (2002). Interferon-alpha enhances biological defence activities against oxidative stress in cultured rat hepatocytes and hepatic stellate cells. J. Med. Invest. 49, 172-181.
29. MUTLU-TURKOGLU, U., ADEMOGLU, E., TURKOGLU, S., BADUR, S., UYSAL, M., and TOKER, G. (1997). The effects of interferon-alpha on serum lipid peroxidation and total thiol content in patients with chronic active hepatitis C. Res. Commun. Mol. Pathol. Pharmacol. 96, 357-361.
30. CAPURON, L., NEURAUTER, G., MUSSELMAN, D.L., LAWSON, D.H., NEMEROFF, C.B., FUCHS, D., and MILLER, A.H. (2003). Interferon-alpha induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol. Psychiatry 54, 906-914.
31. BOTTIGLIERI, T., LAUNDY, M., CRELLIN, R., TOONE, B.K., CARNEY, M.W., and REYNOLDS, E.H. (2000). Homocysteine, folate, methylation, and monoamine metabolism in depression. J. Neurol. Neurosurg. Psychiatry 69, 228-232.